1. Amgen, UCB. EVENITY™ (romosozumab) receives approval in Japan for the treatment of osteoporosis in patients at high risk of fracture [media release]. 8 Jan 2019.
https://www.amgen.com
.
2. McClung MR. Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia. 2018;4(1):11–5.
3. Amgen. Romosozumab (Evenity™): Japanese prescribing information. 2019.
http://www.info.pmda.go.jp/
. Accessed 10 Jan 2019.
4. UCB, Amgen. UCB and Amgen announce FDA advisory committee meeting to review EVENITY(T) (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture [media release]. 30 Nov 2018.
http://www.ucb.com
.
5. Amgen. European Medicines Agency accepts filing for EVENITY(T) (romosozumab) [media release]. 8 Jan 2018.
http://www.amgen.com
.